PACIRA BIOSCIENCES, INC.

NASDAQ: PCRX (Pacira BioSciences, Inc.)

最近更新时间: 4天之前, 6:20PM

24.19

0.12 (0.50%)

前收盘价格 24.07
收盘价格 24.74
成交量 552,877
平均成交量 (3个月) 634,377
市值 1,086,922,496
市盈率 (P/E TTM) 51.47
预期市盈率 (P/E Forward) 7.36
价格/销量 (P/S) 1.53
股市价格/股市净资产 (P/B) 1.42
52周波幅
16.64 (-31%) — 27.64 (14%)
利润日期 6 Nov 2025
营业毛利率 -14.76%
营业利益率 (TTM) 4.63%
稀释每股收益 (EPS TTM) -2.24
季度收入增长率 (YOY) 1.10%
季度盈利增长率 (YOY) -46.40%
总债务/股东权益 (D/E MRQ) 79.70%
流动比率 (MRQ) 2.41
营业现金流 (OCF TTM) 175.75 M
杠杆自由现金流 (LFCF TTM) 144.75 M
资产报酬率 (ROA TTM) 3.56%
股东权益报酬率 (ROE TTM) -12.27%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看涨 混合的
Drug Manufacturers - Specialty & Generic (全球的) 看涨 混合的
股票 Pacira BioSciences, Inc. 看跌 看涨

AIStockmoo 评分

1.0
分析师共识 3.0
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 -1.0
技术振荡指标 4.0
平均 1.00

相关股票

股票 市值 DY P/E(TTM) P/B
PCRX 1 B - 51.47 1.42
RGC 6 B - - 1.22
ANIP 2 B - 53.03 3.63
COLL 2 B - 29.36 5.51
AMPH 1 B - 12.26 1.58
DVAX 1 B - - 2.41

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Value
内部持股比例 1.79%
机构持股比例 110.89%
52周波幅
16.64 (-31%) — 27.64 (14%)
目标价格波幅
28.00 (15%) — 38.00 (57%)
38.00 (HC Wainwright & Co., 57.09%) 购买
33.00 (36.42%)
28.00 (Truist Securities, 15.75%) 购买
平均值 33.00 (36.42%)
总计 2 购买
平均价格@调整类型 22.97
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 17 Nov 2025 38.00 (57.09%) 购买 23.88
Truist Securities 07 Nov 2025 28.00 (15.75%) 购买 22.05

该时间范围内无数据。

日期 类型 细节
03 Dec 2025 公告 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2025 公告 Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
26 Nov 2025 公告 Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
11 Nov 2025 公告 Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
10 Nov 2025 公告 DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
06 Nov 2025 公告 Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
05 Nov 2025 公告 Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
04 Nov 2025 公告 Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
30 Oct 2025 公告 Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
28 Oct 2025 公告 Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
27 Oct 2025 公告 Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
23 Oct 2025 公告 Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
21 Oct 2025 公告 Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
20 Oct 2025 公告 Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
03 Oct 2025 公告 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票